Register

I agree with the Privacy Policy

Los Angeles Times

Medical giant Medtronic to buy rival Covidien for $42.9 billion

June 15, 2014

Because both companies already are giants in the medical-devices market, the merger should allow for more robust research and development and more comprehensive health-monitoring capabilities, said Harry Wang, a health industry analyst at product research firm Parks Associates.

The medical devices industry has been plagued by slow innovation, but the merger should advance the market, Wang said.

“By buying up this company and consolidating R&D spending, they have a better chance of getting their products to market,” he said. “Over the long term, if R&D is spent wisely and effectively, you will see more cost-effective products for consumers.”

From the article, "Medical giant Medtronic to buy rival Covidien for $42.9 billion" by Javier Panzar.

Previously In The News

Wearable devices are unlikely to be big sellers, analysts say

Still, amid signs of a slowdown in smartphone sales and pressure to come up with the next big thing, tech companies are jumping on the wearable tech trend. Many analysts expect Apple, Google and Sa...

Apple Watch goes beyond being a wrist-sized smartphone

The Apple Watch enters a tiny market for now, though Apple’s marketing and advertising muscle could change that. Just 4% of U.S. households with high-speed Internet say they are likely to purchase...

Sling TV beefs up its basic lineup and adds a movie tier

A new study by Parks Associates lends support to Bhise's statement about the potential demand. In U.S. homes with broadband, Parks reported, nearly half of the video viewed on the television was fr...

Snapchat brings in $538 million from investors

Snapchat's co-founder and chief executive, Evan Spiegel, who turns 25 on Thursday, said this week that the company plans an IPO, though he declined to offer a timeline. The new cash will help e...

‹
1
2
3
4
5
6
7
8
9
10
›